by: Parent Project Muscular Dystrophy
Capricor Therapeutics recently joined PPMD for a community webinar update to discuss the HOPE-2 trial.
During the webinar, Capricor provided a background of CAP-1002 and its clinical development to date that has led to the trial. The webinar also reviewed the trial design, eligibility criteria, and assessments that participants will need to complete if they participate in the trial, as well as the travel policy for participants who need to travel to a trial site.
